1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Panchsheel Organics Limited

Panchsheel Organics Limited

BBSE:PANCHSHEEL
96.90
INR
-6.15
(-5.97%)
7.82EPS
15.09P/E
1.55BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
39.06
35.69
40.27
37.76
40.8
48.08
50.23
97.72
68.8
93.27
79.87
81.3
80.99
81.86
Basic EPS, GAAP
1.75
1.89
3.03
3.2
3.66
4.02
5.27
9.98
8.33
12.78
10.71
10.47
8.22
7.82
Free Cash Flow per Basic Share
2.24
-0.12
-0.28
-0.71
2.27
1.48
4.07
6.19
-3.27
-3.55
-0.25
-8.9
2.58
- -
Dividend per Share
0.04
0.29
0.6
0.45
0.4
0.47
0.49
1.28
0.66
3.21
2.68
3
3.2
- -
Book Value per Share
17.45
18.45
21.18
23.77
26.89
30.39
35.2
39.56
47.26
81.54
94.93
101.63
135.61
- -
Tangible Book Value per Share
17.45
18.45
21.18
23.77
26.89
30.39
35.2
39.56
47.26
81.54
94.93
101.63
135.61
- -
Basic Weighted Avg Shares
10
10
10
10
10
10
10
5
10
11
13
13
13
13
Sales/Revenue/Turnover
392
358
404
379
409
482
504
490
690
1,027
1,052
1,071
1,067
1,078
Operating Margin (%)
8.61
13.86
11.16
14.43
14.32
12.35
15.7
16.05
16.81
17.8
16.37
14.38
10.52
9.86
Depreciation Expense
11
15
13
12
12
12
11
11
12
16
17
22
23
24
Net Income, GAAP
18
19
30
32
37
40
53
50
84
141
141
138
108
103
Effective Tax Rate (%)
34.77
31.28
27.23
36.01
29.17
28.65
27.65
31.37
26.67
26.22
27.24
23.77
25.14
25.33
Profit Margin (%)
4.49
5.3
7.53
8.48
8.98
8.37
10.5
10.21
12.11
13.7
13.41
12.88
10.15
9.55
Working Capital
118
148
150
154
177
210
250
271
383
525
733
645
632
- -
LT Debt
6
21
15
10
6
1
- -
10
10
5
3
2
1
- -
Total Equity
175
185
212
238
270
305
353
397
474
961
1,250
1,339
1,408
- -
Return on Invested Capital (%)
7.89
7.96
11.95
10.74
12.18
11.82
14.21
12.16
17.56
17.5
10.71
8.67
5.87
- -
Return on Capital (%)
9.85
9.7
13.23
12.19
12.59
12.33
14.39
12.4
17.68
18.54
12.17
10.24
7.64
- -
Return on Common Equity (%)
10.49
10.55
15.3
14.24
14.46
14.05
16.08
13.35
19.19
19.61
12.76
10.66
7.89
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
56
- -
LT Borrowings
- -
1
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
10
13
Market Capitalization
1,711
937
1,554

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
895
- -
Cash, Cash Equivalents & STI
- -
38
- -
Accounts Receivable, Net
- -
392
- -
Inventories
- -
451
- -
Total Current Liabilities
- -
264
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
56
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.11%
32.9%
5.21%
Free Cash Flow
295.74%
621.95%
-128.99%
Net Income, GAAP
16.75%
22.37%
-21.49%
Sales/Revenue/Turnover
11.49%
18.7%
-0.38%
Total Cash Common Dividend
46.91%
90.61%
6.56%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
261
272
262
284
1,071
2026
236
253
267
311
1,067
2027
247
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.6
2.88
2.79
2.41
10.47
2026
2.16
1.98
2.79
1.29
8.22
2027
1.76
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3
2026
- -
- -
- -
- -
3.2
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kishore Abhaychand Turakhia
Full Time Employees
191
Sector
Health technology
Industry
Pharmaceuticals: major
Address
137, 138, Hubtown Solaris Mumbai MA India 400069
IPO Date
Feb 16, 1996
Website
panchsheelorganics.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Panchsheel Organics Limited, founded in 1989 and headquartered in Mumbai with manufacturing facilities in Indore, Madhya Pradesh, manufactures and exports active pharmaceutical ingredients, intermediates, finished formulations for human and veterinary use; nutraceuticals; vitamins, hormones, and steroids; agri biotech products including biofertilizers, biostimulants, and growth promoters; aquaculture products; dehydrated culture media; probiotics and enzymes; micro pellets, direct compression granules, and sustained/modified release pellets; as well as specialty chemicals such as insecticides, herbicides, pesticides, fungicides, viricides, water-soluble fertilizers, and plant growth regulators. The company operates primarily from India with exports to international markets and offers custom synthesis, contract manufacturing, and job work for APIs, drug intermediates, and formulations; its product portfolio spans categories like cardiovascular, neuropsychiatry, antifungal, fluoroquinolones, antiallergic, anti-inflammatory, gastrointestinal, oncology, over-the-counter remedies, and animal health supplements. In recent developments, Panchsheel Organics allotted equity shares on a preferential basis in September 2022 to fund Phase 1 capex of Rs 40 crore at Pithampur and Indore for probiotics and enzymes production with 36-40 TPA capacity targeting Rs 40-50 crore revenue by FY25; it is advancing Phase 2 capex of Rs 50-70 crore at DMIC Vikram Udyogpuri Biotech Park for fermentation-based and API pharmaceuticals adding 36-40 TPA fermentation and 120 TPA API capacity; the board declared an interim dividend for the quarter ended June 30, 2025 in August 2025 and continues reporting steady financial results including unaudited quarterly outcomes through September 2025.